NNVCNANOVIRICIDES, INC.

NYSE nanoviricides.com


$ 2.17 $ -0.03 (-1.35 %)    

Tuesday, 28-May-2024 14:08:42 EDT
QQQ $ 454.82 $ 1.73 (0.38 %)
DIA $ 398.57 $ -2.04 (-0.52 %)
SPY $ 530.36 $ 0.37 (0.07 %)
TLT $ 91.26 $ -1.31 (-1.43 %)
GLD $ 225.37 $ 2.27 (1.05 %)
$ 2.2
$ 2.17
$ 0.00 x 0
$ 0.00 x 0
$ 2.15 - $ 2.21
$ 1.00 - $ 2.35
105,744
na
25.92M
$ -0.03
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-15-2024 03-31-2024 10-Q
2 02-14-2024 12-31-2023 10-Q
3 11-14-2023 09-30-2023 10-Q
4 10-13-2023 06-30-2023 10-K
5 05-15-2023 03-31-2023 10-Q
6 02-14-2023 12-31-2022 10-Q
7 11-14-2022 09-30-2022 10-Q
8 10-13-2022 06-30-2022 10-K
9 05-16-2022 03-31-2022 10-Q
10 02-14-2022 12-31-2021 10-Q
11 11-15-2021 09-30-2021 10-Q
12 10-12-2021 06-30-2021 10-K
13 05-14-2021 03-31-2021 10-Q
14 02-16-2021 12-31-2020 10-Q
15 11-16-2020 09-30-2020 10-Q
16 10-13-2020 06-30-2020 10-K
17 06-22-2020 03-31-2020 10-Q
18 02-14-2020 12-31-2019 10-Q
19 11-15-2019 09-30-2019 10-Q
20 08-23-2019 06-30-2019 10-K
21 05-15-2019 03-31-2019 10-Q
22 02-14-2019 12-31-2018 10-Q
23 11-14-2018 09-30-2018 10-Q
24 10-12-2018 06-30-2018 10-K
25 05-21-2018 03-31-2018 10-Q
26 02-20-2018 12-31-2017 10-Q
27 11-14-2017 09-30-2017 10-Q
28 09-28-2017 06-30-2017 10-K
29 05-15-2017 03-31-2017 10-Q
30 02-14-2017 12-31-2016 10-Q
31 11-14-2016 09-30-2016 10-Q
32 09-16-2016 06-30-2016 10-K
33 05-10-2016 03-31-2016 10-Q
34 02-09-2016 12-31-2015 10-Q
35 11-09-2015 09-30-2015 10-Q
36 09-14-2015 06-30-2015 10-K
37 05-15-2015 03-31-2015 10-Q
38 02-24-2015 12-31-2014 10-Q
39 11-14-2014 09-30-2014 10-Q
40 09-29-2014 06-30-2014 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 nanoviricides-reports-breakthrough-in-treating-airborne-viruses-boosting-lifespan-in-infected-mice

 NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, says that ...

 ef-hutton-reiterates-buy-on-nanoviricides-maintains-65-price-target

EF Hutton analyst Tim Moore reiterates Nanoviricides (AMEX:NNVC) with a Buy and maintains $6.5 price target.

 nanoviricides-broad-spectrum-antiviral-nv-387-offers-protection-against-influenza-a-and-bird-flu

NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, says that t...

 ef-hutton-reiterates-buy-on-nanoviricides-maintains-65-price-target

EF Hutton analyst Tim Moore reiterates Nanoviricides (AMEX:NNVC) with a Buy and maintains $6.5 price target.

 nanoviricides-q2-eps-018-down-from-015-yoy-as-of-december-31-2023-we-had-cash-and-cash-equivalent-current-assets-balance-of-approximately-531m-additional-agreements-have-resulted-in-a-further-approximately-25m-available-cash

Nanoviricides (AMEX:NNVC) reported quarterly losses of $(0.18) per share. This is a 20 percent decrease over losses of $(0.15) ...

 nanoviricides-reported-that-the-phase-1a1b-human-clinical-trial-of-nv-cov-2-the-companys-broad-spectrum-antiviral-drug-is-progressing-successfully

The Company reports that its Indian collaborator and drug sponsor, Karveer Meditech Pvt. Ltd., India, has communicated that a...

 why-are-nanoviricides-shares-gaining-today

NanoViricides Inc (NYSE: NNVC) shares are trading higher after the company reported preclinical data from an antiviral clinical...

 why-better-therapeutics-are-trading-higher-by-51-here-are-20-stocks-moving-premarket

Gainers CytoMed Therapeutics Limited (NASDAQ: GDTC) shares surged 109.2% to $7.30 in pre-market trading after gaining 9% on ...

 nanoviricides-says-clinical-trial-of-broad-spectrum-antiviral-drug-nv-cov-2-is-progressing-well---nv-cov-2-is-positioned-to-fulfill-many-unmet-medical-needs

NanoViricides, Inc. (NYSE American: NNVC) (the “Company”) reports that the clinical trial of its broad-spectrum antiviral drug ...

 nanoviricides-says-clinical-trial-of-its-broad-spectrum-antiviral-drug-nv-cov-2-is-progressing-satisfactorily

Following safety and tolerability evaluation in healthy persons for a single escalating dose of NV-CoV-2 Oral Syrup or NV-CoV-2...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION